Lifecare ASA: Last day of the subscription period for the Rights Issue

21 Jan 2026 07:00 CET

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the previous stock exchange announcements by Lifecare ASA
("Lifecare" or the "Company") regarding the partially underwritten rights
issue of new shares in the Company (the "Offer Shares") with preferential
subscription rights for existing shareholders (the "Subscription Rights"),
raising gross proceeds of minimum NOK 80 million and up to NOK 100 million
(the "Rights Issue").

The subscription period for the Rights Issue will expire at 16:30 (CET) today,
21 January 2026. Over-subscription and subscription without Subscription
Rights is permitted, however, there can be no assurance that Offer Shares will
be allocated for such subscriptions.

Subscription Rights that are not used to subscribe for Offer Shares before the
end of the subscription period, will have no value and lapse without
compensation to the holder.

In order to subscribe for Offer Shares, investors must complete the
subscription form attached as appendix A to the prospectus for the Rights
Issue dated 6 January 2026 (the "Prospectus"), and submit it to one of the
Managers (as defined below) in accordance with the instructions set out in
Section 13.10.2 "Subscription procedure" of the Prospectus, by 16:30 hours
(CET) on 21 January 2026. Subscribers who are Norwegian citizens may subscribe
for Offer Shares by following the link on www.dnb.no/emisjoner and
www.sb1markets.no/transaksjoner/, which will redirect the subscriber to the
VPS online subscription system. In order to use the online subscription
system, the subscriber must have, or obtain, a VPS account number.

For more information, and the complete terms and conditions of the Rights
Issue, please refer to the Prospectus. Subject to regulatory restrictions in
certain jurisdictions, the Prospectus is available at www.lifecare.no,
www.dnb.no/emisjoner, and www.sb1markets.no/transaksjoner/. Subscriptions may
only be made on the basis of the Prospectus.

Important information

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The securities of the Company may not be
offered or sold in the United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the "U.S.
Securities Act"). The securities of the Company have not been, and will not
be, registered under the U.S. Securities Act. Any sale in the United States of
the securities mentioned in this communication will be made solely to
"qualified institutional buyers" as defined in Rule 144A under the U.S.
Securities Act. No public offering of the securities will be made in the
United States.

Any offering of the securities referred to in this announcement will be made
by means of the Prospectus. This announcement is an advertisement and is not a
prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a
regulated market, and repealing Directive 2003/71/EC (as amended) as
implemented in any EEA Member State (the "Prospectus Regulation"). Investors
should not subscribe for any securities referred to in this announcement
except on the basis of information contained in the Prospectus. Copies of the
Prospectus will, following publication, be available from the Company's
registered office and, subject to certain exceptions, on the websites of DNB
Carnegie, a part of DNB Bank ASA, and SB1 Markets AS (the "Managers").

This announcement is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, the United States, or any other
jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.

The Managers are acting for the Company in connection with the Rights Issue
and no one else and will not be responsible to anyone other than the Company
for providing the protections afforded to their respective clients or for
providing advice in relation to the Rights Issue or any transaction or
arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "anticipate", "believe",
"continue", "estimate", "expect", "intends", "may", "should", "will" and
similar expressions. The forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that these assumptions were
reasonable when made, these assumptions are inherently subject to significant
known and unknown risks, uncertainties, contingencies, and other important
factors which are difficult or impossible to predict and are beyond its
control. Such risks, uncertainties, contingencies, and other important factors
could cause actual events to differ materially from the expectations expressed
or implied in this release by such forward-looking statements. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without
notice. This announcement is made by and is the responsibility of the Company.
Neither the Managers nor any of their respective affiliates make any
representation as to the accuracy or completeness of this announcement and
none of them accepts any responsibility for the contents of this announcement
or any matters referred to herein.

This announcement is for information purposes only and is not to be relied
upon in substitution for the exercise of independent judgment. It is not
intended as investment advice and under no circumstances is it to be used or
considered as an offer to sell, or a solicitation of an offer to buy any
securities or a recommendation to buy or sell any securities of the Company.
No reliance may be placed for any purpose on the information contained in this
announcement or its accuracy, fairness, or completeness. Neither the Managers
nor any of their respective affiliates accept any liability arising from the
use of this announcement.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-01-21 07:00 CET.

More information:
Access the news on Oslo Bors NewsWeb site

663936_Lifecare ASA- Last day of the subscription period for the Rights Issue.pdf